Cytosorbents Corporation (CTSO)
CTSO Stock Price Chart
Explore Cytosorbents Corporation interactive price chart. Choose custom timeframes to analyze CTSO price movements and trends.
CTSO Company Profile
Discover essential business fundamentals and corporate details for Cytosorbents Corporation (CTSO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
8 Aug 2006
Employees
149.00
Website
https://www.cytosorbents.comCEO
Phillip Chan
Description
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
CTSO Financial Timeline
Browse a chronological timeline of Cytosorbents Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Nov 2026
EPS estimate is -$0.03, while revenue estimate is $10.17m.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.05, while revenue estimate is $9.39m.
Earnings released on 13 May 2026
EPS came in at -$0.08 falling short of the estimated -$0.06 by -33.33%, while revenue for the quarter reached $8.86m , missing expectations by -5.70%.
Earnings released on 25 Mar 2026
EPS came in at -$0.09 falling short of the estimated -$0.05 by -80.00%, while revenue for the quarter reached $9.23m , missing expectations by -5.58%.
Earnings released on 13 Nov 2025
EPS came in at -$0.04 surpassing the estimated -$0.06 by +33.33%, while revenue for the quarter reached $9.49m , beating expectations by +2.93%.
Earnings released on 7 Aug 2025
EPS came in at -$0.05 surpassing the estimated -$0.07 by +28.57%, while revenue for the quarter reached $9.62m , beating expectations by +4.29%.
Earnings released on 14 May 2025
EPS came in at -$0.06 surpassing the estimated -$0.08 by +25.00%, while revenue for the quarter reached $8.73m , missing expectations by -3.11%.
Earnings released on 31 Mar 2025
EPS came in at -$0.03 surpassing the estimated -$0.07 by +57.14%, while revenue for the quarter reached $6.52m , missing expectations by -35.33%.
Earnings released on 7 Nov 2024
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%, while revenue for the quarter reached $8.61m , missing expectations by -8.89%.
Earnings released on 13 Aug 2024
EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%, while revenue for the quarter reached $9.89m , beating expectations by +2.22%.
Earnings released on 9 May 2024
EPS came in at -$0.12 matching the estimated -$0.12, while revenue for the quarter reached $9.79m , beating expectations by +0.06%.
Earnings released on 14 Mar 2024
EPS came in at -$0.12 surpassing the estimated -$0.14 by +14.29%, while revenue for the quarter reached $8.67m , missing expectations by -6.59%.
Earnings released on 9 Nov 2023
EPS came in at -$0.21 falling short of the estimated -$0.12 by -75.00%, while revenue for the quarter reached $7.75m , missing expectations by -17.77%.
Earnings released on 1 Aug 2023
EPS came in at -$0.14 falling short of the estimated -$0.11 by -27.27%, while revenue for the quarter reached $8.07m , missing expectations by -26.81%.
Earnings released on 2 May 2023
EPS came in at -$0.17 falling short of the estimated -$0.13 by -30.77%, while revenue for the quarter reached $7.91m , missing expectations by -9.39%.
Earnings released on 9 Mar 2023
EPS came in at -$0.01 surpassing the estimated -$0.17 by +94.12%, while revenue for the quarter reached $7.64m , missing expectations by -12.36%.
Earnings released on 3 Nov 2022
EPS came in at -$0.28 falling short of the estimated -$0.16 by -75.00%, while revenue for the quarter reached $6.46m , missing expectations by -27.94%.
Earnings released on 2 Aug 2022
EPS came in at -$0.25 falling short of the estimated -$0.14 by -78.57%, while revenue for the quarter reached $7.33m , missing expectations by -23.44%.
Earnings released on 3 May 2022
EPS came in at -$0.21 falling short of the estimated -$0.15 by -40.00%, while revenue for the quarter reached $7.92m , missing expectations by -18.47%.
Earnings released on 8 Mar 2022
EPS came in at -$0.21 falling short of the estimated -$0.13 by -61.54%, while revenue for the quarter reached $9.70m , beating expectations by +0.17%.
Earnings released on 4 Nov 2021
EPS came in at -$0.15 falling short of the estimated -$0.12 by -25.00%, while revenue for the quarter reached $8.90m , missing expectations by -25.57%.
Earnings released on 3 Aug 2021
EPS came in at -$0.11 falling short of the estimated -$0.04 by -181.04%, while revenue for the quarter reached $11.37m , missing expectations by -7.37%.
CTSO Stock Performance
Access detailed CTSO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
